Granted Patent
B2
US 12,709,639 · App. 18/497,745 · Granted Aug 18, 2026
Methods of administering chimeric antigen receptor immunotherapy
Assignee:
Kite Pharma, Inc.
C07K14/7051A61K9/0019A61K40/11A61K40/31A61K40/4211A61P35/00C07K16/248A61K31/573A61K38/1816A61K38/193A61K38/31A61K38/34A61K38/35A61K38/38A61K2039/804A61K2239/31A61K2239/38A61K2239/48
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The disclosure provides cells comprising CD19-directed chimeric antigen receptor (CAR) genetically modified autologous T cell immunotherapy for the treatment of, e.g., relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma. Some aspects of the disclosure relate to methods of treatment and monitoring following infusion of T cell therapy provided herein.
Claims (19)
1 . A method for treating, high grade B-cell lymphoma in a patient comprising:
administering to the patient in need thereof an axicabtagene ciloleucel suspension by intravenous infusion at a dose between about 1×10 6 and about 2×10 6 CAR-positive viable T cells per kg body weight up to a maximum dose of about 2×10 8 CAR-positive viable T cells,
wherein axicabtagene ciloleucel is a CD19-directed genetically modified autologous T cell immunotherapy, comprising the patient's own T cells harvested and genetically modified ex vivo by retroviral transduction to express a chimeric antigen receptor (CAR) comprising an anti-CD19 single chain variable fragment (scFv) linked to CD28 and CD3-zeta co-stimulatory domains.
2 . The method of claim 1 , wherein the intravenous infusion is for a time period between 15 and 120 minutes.
3 . The method of claim 1 , wherein the intravenous infusion is for a time period up to 30 minutes.
4 . The method of claim 1 , wherein between 50 and 100 mL of the axicabtagene ciloleucel suspension is administered.
5 . The method of claim 1 , wherein about 68 mL of the axicabtagene ciloleucel suspension is administered.
6 . The method of claim 1 , wherein the axicabtagene ciloleucel suspension is infused from an infusion bag.
7 . The method of claim 6 , wherein the infusion bag is agitated during the infusion.
8 . The method of claim 1 , wherein the axicabtagene ciloleucel suspension is administered within 3 hours after thawing.
9 . The method of claim 1 , wherein the axicabtagene ciloleucel suspension further comprises albumin.
10 . The method of claim 9 , wherein albumin is present in an amount of about 2-3% (v/v).
11 . The method of claim 1 , wherein the axicabtagene ciloleucel suspension further comprises DMSO.
12 . The method of claim 1 , further comprising monitoring the patient for symptoms of cytokine release syndrome (CRS) daily for 7-10 days following the infusion, and administering to the patient a steroid:
(a) when CRS Grade 3 is observed; or
(b) when CRS Grade 2 is observed and treated but CRS symptoms do not improve after 24 hours.
13 . The method of claim 12 , wherein the monitoring is daily for 7 days following the infusion.
14 . The method of claim 12 , wherein the steroid is a corticosteroid.
15 . The method of claim 14 , wherein the corticosteroid is methylprednisolone or dexamethasone.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded May 22, 2025
From: WIEZOREK, JEFFREY S.
To: KITE PHARMA, INC.
Reel/Frame 071203/0004 →
Continuity (3)
Provisional Application
62574159
· Oct 18, 2017
Related Publication
20240058381A1
· Feb 22, 2024
References Cited (370)
US 4946778A
· Ladner et al.
· 1990
[cited by applicant]
US 5091513A
· Huston et al.
· 1992
[cited by applicant]
US 5132405A
· Huston et al.
· 1992
[cited by applicant]
US 5545806A
· Lonberg et al.
· 1996
[cited by applicant]
US 5545807A
· Surani et al.
· 1996
[cited by applicant]
US 5569825A
· Lonberg et al.
· 1996
[cited by applicant]
US 5591827A
· Brakenhoff et al.
· 1997
[cited by applicant]
US 5625126A
· Lonberg et al.
· 1997
[cited by applicant]
US 5633425A
· Lonberg et al.
· 1997
[cited by applicant]
US 5661016A
· Lonberg et al.
· 1997
[cited by applicant]
US 5728388A
· Terman
· 1998
[cited by applicant]
US 5827642A
· Riddell et al.
· 1998
[cited by applicant]
US 5830462A
· Crabtree et al.
· 1998
[cited by applicant]
US 5834266A
· Crabtree et al.
· 1998
[cited by applicant]
US 5869337A
· Crabtree et al.
· 1999
[cited by applicant]
US 6040177A
· Riddell et al.
· 2000
[cited by applicant]
US 6165787A
· Crabtree et al.
· 2000
[cited by applicant]
US 6319494B1
· Capon et al.
· 2001
[cited by applicant]
US 6410319B1
· Raubitschek et al.
· 2002
[cited by applicant]
US 6797514B2
· Berenson et al.
· 2004
[cited by applicant]
US 6867041B2
· Berenson et al.
· 2005
[cited by applicant]
US 6905874B2
· Berenson et al.
· 2005
[cited by applicant]
US 7709226B2
· Foote
· 2010
[cited by applicant]
US 7741465B1
· Eshar et al.
· 2010
[cited by applicant]
US 8211422B2
· Eshhar et al.
· 2012
[cited by applicant]
US 8486693B2
· Park et al.
· 2013
[cited by applicant]
US 8562991B2
· Igawa et al.
· 2013
[cited by applicant]
US 8679492B2
· Blein et al.
· 2014
[cited by applicant]
US 9296820B2
· Umana et al.
· 2016
[cited by applicant]
US 9834590B2
· Campana et al.
· 2017
[cited by applicant]
US 9855298B2
· Bot et al.
· 2018
[cited by applicant]
US 9987308B2
· Riddell et al.
· 2018
[cited by applicant]
US 20020006409A1
· Wood
· 2002
[cited by applicant]
US 20070014720A1
· Gazit-Bornstein et al.
· 2007
[cited by applicant]
US 20100104509A1
· King et al.
· 2010
[cited by applicant]
US 20120093842A1
· Eshhar et al.
· 2012
[cited by applicant]
US 20130266551A1
· Campana et al.
· 2013
[cited by applicant]
US 20140134195A1
· Russell
· 2014
[cited by applicant]
US 20140286934A1
· Blein et al.
· 2014
[cited by applicant]
US 20150202286A1
· June et al.
· 2015
[cited by applicant]
US 20150344844A1
· Better et al.
· 2015
[cited by applicant]
US 20190151361A1
· Wiezorek
· 2019
[cited by applicant]
US 20190358262A1
· Albertson
· 2019
[cited by applicant]
US 20190388471A1
· June et al.
· 2019
[cited by applicant]
US 20200283729A1
· Loew et al.
· 2020
[cited by applicant]
US 20210145304A1
· Visweswara et al.
· 2021
[cited by applicant]
US 20220160729A1
· Deisher
· 2022
[cited by applicant]
US 20220281976A1
· Rosenthal et al.
· 2022
[cited by applicant]
US 20220387492A1
· Bot et al.
· 2022
[cited by applicant]
US 20220389449A1
· Paul et al.
· 2022
[cited by applicant]
US 20230255962A1
· Boiko et al.
· 2023
[cited by applicant]
US 20230374105A1
· Bitter et al.
· 2023
[cited by applicant]
US 20240058381A1
· Wiezorek
· 2024
[cited by applicant]
US 20240279665A1
· Zhao et al.
· 2024
[cited by applicant]
US 20250002579A1
· Cooper et al.
· 2025
[cited by applicant]
CN 103820393
· 2014
[cited by applicant]
CN 106701827
· 2017
[cited by applicant]
CN 108384760A
· 2018
[cited by applicant]
WO WO2007002223
· 2007
[cited by applicant]
WO WO2008081035A1
· 2008
[cited by applicant]
WO WO2009091826
· 2009
[cited by applicant]
WO WO2012033885
· 2012
[cited by applicant]
WO WO201207900A1
· 2012
[cited by applicant]
WO WO2012079000
· 2012
[cited by applicant]
WO WO201212954A1
· 2012
[cited by applicant]
WO WO2012138475
· 2012
[cited by applicant]
WO WO2013123061A1
· 2013
[cited by applicant]
WO WO2013154760
· 2013
[cited by applicant]
WO WO2014055657
· 2014
[cited by applicant]
WO WO2014127261
· 2014
[cited by applicant]
WO WO2014153270
· 2014
[cited by applicant]
WO WO2014184744
· 2014
[cited by applicant]
WO WO2014186469
· 2014
[cited by applicant]
WO WO2015075468
· 2015
[cited by applicant]
WO WO2015080981
· 2015
[cited by applicant]
WO WO2015090229
· 2015
[cited by applicant]
WO WO2015120096
· 2015
[cited by applicant]
WO WO2015120096A2
· 2015
[cited by examiner]
WO WO2016044745
· 2016
[cited by applicant]
WO WO2016090369
· 2016
[cited by applicant]
WO WO2016210293A1
· 2016
[cited by applicant]
WO WO2017025038A1
· 2017
[cited by applicant]
WO WO2017015783
· 2017
[cited by applicant]
WO WO2017222593A1
· 2017
[cited by applicant]
WO WO2018145648
· 2018
[cited by applicant]
WO WO2018161017
· 2018
[cited by applicant]
WO WO2018213337
· 2018
[cited by applicant]
Locke et al. Updated Phase 1 Results from ZUMA-1: A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 (Anti-CD19 CAR T Cells) in Subjects with Refractory Aggressive Non-(Molecular Therapy vol. 2…
[cited by examiner]
Locke 2017 Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma (Molecular Therapy vol. 25 No. 1 Jan. 2017 (Year: 2017).
[cited by examiner]
Lee et alCurrent concepts in the diagnosis and management of cytokine release syndrome (Blood Jul. 10, 2014, vol. 124, No. 2) (Year: 2014).
[cited by examiner]
Park Adoptive Transfer of Chimeric Antigen Receptor Re-directed Cytolytic T Lymphocyte Clones in Patients with Neuroblastoma (Molecular Therapy vol. 15 No. 4, Apr. 2007) (Year: 2007).
[cited by examiner]
Decision of Final Rejection for Japanese Application No. 2020-521585 dated Apr. 18, 2023. 9 pages.
[cited by applicant]
Examination Report for Australian Application No. 2021282551 dated Dec. 14, 2022. 4 pages.
[cited by applicant]
Examination Report for Australian Application No. 2021282551 dated Nov. 7, 2022. 5 pages.
[cited by applicant]
Galon, Journal of Clinical Oncology (May 2017), vol. 35, No. 15 suppl., abstract 3025, ascopubs.org/doi/10.1200/JCO.2017.35.15_suppl.3025. 4 pages.
[cited by applicant]
Notice of Final Rejection for Korean Application No. 10-2020-7013686 dated Oct. 6, 2022. 8 pages.
[cited by applicant]
Office Action and Search Report for Chinese Application No. 201880067426.5 dated Feb. 4, 2023. 13 pages.
[cited by applicant]
Office Action for Japanese Application No. 2020-521585 dated Oct. 25, 2022. 8 pages.
[cited by applicant]
Office Action with Search Report for Taiwan Application No. 107136797 dated Sep. 15, 2022. 12 pages.
[cited by applicant]
Examination Report for Australian Patent Application No. 2021282551 dated Jul. 29, 2022. 5 pages.
[cited by applicant]
Examination Report for Australian Patent Application No. 2021282551 dated May 9, 2022. 4 pages.
[cited by applicant]
Notice of Final Rejection Korean for Patent Application No. 10-2020-7013686 dated Jun. 3, 2022. 7 pages.
[cited by applicant]
Office Action for Canadian Patent Application No. 3,084,470 dated Mar. 23, 2022. 4 pages.
[cited by applicant]
Official Action for Argentinian Patent Application No. 20180103032 dated Feb. 15, 2022. 9 pages.
[cited by applicant]
Examination Report for Australia Patent Application No. 2018351046 dated Nov. 17, 2021. 4 pages.
[cited by applicant]
Notice of Preliminary Rejection for Korean Patent Application No. 10-2020-7013686 dated Oct. 14, 2021. 13 pages.
[cited by applicant]
Brudno et al. Toxicities of chimeric antigen receptor T cells: recognition and management. Blood, Jun. 30, 2016, vol. 127, No. 26 (Year: 2016).
[cited by applicant]
Locke et al. Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Agressive Lymphoma. Molecular Therapy vol. 25 No. 1 Jan. 2017 (Year: 2017).
[cited by applicant]
Gust et al. Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells. Published OnlineFirst Oct. 12, 2017; DOI: 10.1158/2159-8290.CD-17-0698. (Year: 2…
[cited by applicant]
Examination Report issued on Canadian application counterpart 3,084,470, mailed Mar. 23, 2021.
[cited by applicant]
Locke et al., Abstract CT019: Primary results from ZUME-1: a pivotal trial of axicabtagene ciloleucel (axicel; KTEC19) in patients with refractory aggressive non-Hodgkin lymphoma (NHL); Cancer research vol. 77/Supplemen…
[cited by applicant]
Lee et al. Current concepts in the diagnosis and management of cytokine release syndromeBLOOD, Jul. 10, 2014 x vol. 124 , No. 2 (Year: 2014).
[cited by applicant]
Locke et al. Updated Phase 1 Results from ZU MA-1. Molecular Therapy vol. 24, Supplement 1, May 2016 (Year: 2016).
[cited by applicant]
Lu et al. A Rapid Cell Expansion Process for Production of Engineered Autologous CAR-T Cell Therapies. Hu Man Gene Therapy Methods, vol. 27 No. 6: 2016 (Year: 2016).
[cited by applicant]
Park et al. Adoptive Transfer of Chimeric Antigen Receptor Re-directed Cytolytic T Lymphocyte Clones in Patients with Neuroblastoma. (Year: 2007).
[cited by applicant]
Examination Report dated Dec. 16, 2020 for counterpart Australian Patent Application No. 2018351046.
[cited by applicant]
Intl. Search Report-Written Opinion dated Feb. 4, 2019 for Intl. Appl. No. PCT/US2018/056467.
[cited by applicant]
Intl. Preliminary Report on Patentability-Written Opinion dated Apr. 21, 2020 for Intl. Appl. No. PCT/US2018/056467.
[cited by applicant]
Kochenderfer mmunother., et 32(7): al., 689-702 “Construction (2009) and Pre-clinical Evaluation of an Anti-CD19 Chimeric Antigen Receptor”, J immunother., 32(7): 689-702 (2009).
[cited by applicant]
Ruella et al., “Chimeric Antigen Receptor T cells for B Cell Neoplasms: Choose the Right CAR for You”, Curr Hematol Malig Rep, 11:368-384 (2016).
[cited by applicant]
Sadelain et al, “The Basic Principles of Chimeric Antigen Receptor Design”, Cancer Discovery, 3:388-398 (2013).
[cited by applicant]
Frederick L. Locke et al., “Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma”, Molecular Therapy, Jan. 2017, pp. 285-295, vol. 25, No. 1.
[cited by applicant]
J. N. Kochenderfer et al., “Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor”, J…
[cited by applicant]
Jennifer N. Brudno et al., “Toxicities of Chimeric Antigen Receptor T Cells: Recognition and Management,” Blood, May 20, 2016 (online), pp. 3321-3330, vol. 127, No. 26.
[cited by applicant]
Tangying Lily Lu et al., “A Rapid Cell Expansion Process for Production of Engineered Autologous CAR-T Cell Therapies”, Human Gene Therapy Methods, 2016, pp. 209-218, vol. 27, No. 6.
[cited by applicant]
Marcus P. Watkins et al., “CD19-targeted Immunotherapies for Treatment of Patients with non-Hodgkin B-cell Lymphomas”, Expert Opinion on Investigational Drugs, 2018., pp. 601-611, vol. 27, No. 7.
[cited by applicant]
Sattva S. Neelapu et al., “Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma”, The New England Journal of Medicine, Dec. 28, 2017, pp. 2531-2544, vol. 377, No. 26.
[cited by applicant]
Highlights of Prescribing Information for ACTEMRA® (tocilizumab) Aug. 2017. 43 pages.
[cited by applicant]
Jensen, et al. Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans. Biology of blood and marrow tran…
[cited by applicant]
Whitlow, et al. An improved linker for single-chain Fv with reduced aggregation and enhanced proteolytic stability. Protein Engin. 1993; 6(8):989-995.
[cited by applicant]
Abramson et al., High Durable CR Rates in Relapsed/Refractory (R/R) Aggressive B-NHL Treated with the CD19-Directed Car T Cell Product JCAR017 (Transcend NHL 001): Defined Composition Allows for Dose-Finding and Definit…
[cited by applicant]
Al-Lazikani et al., “Standard conformations for the canonical structures of immunoglobulins” J Mol Bioi 273: 927-948 (1997).
[cited by applicant]
Akbar et al., “A compact vocabulary of paratope-epitope interactions enables predictability of antibody-antigen binding,” Cell Reports, 34 pp. 1-21 (Year: 2021).
[cited by applicant]
Alabanza et al., “Function of Novel Anti-CD19 Chimeric Antigen Receptors with Human Variable Regions Is Affected by Hinge and Transmembrane Domains,” Mol. Ther., 25(11), 2452-2465 (Epub Jul. 2017. 27).
[cited by applicant]
Ando et al., A Safeguard System for Induced Pluripotent Stem Cell-Derived Rejuvenated T Cell Therapy, Stem Cell Reports 2015, vol. 5, pp. 597-608.
[cited by applicant]
Arnon et al., “Monoclonal Antibodies and Cancer Therapy”, pp. 243-256, Alan R. Liss, Inc. (1985).
[cited by applicant]
Barbas et al., “Recombinant human Fab fragments neutralize human type 1 immunodeficiency virus in vitro”, Proc. Natl. Acad. Sci. USA, 89(19): 9339-43 (1992).
[cited by applicant]
Beatty et al., “Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce antitumor activity in solid malignancies,” Cancer Immunology Research, 2(2), 112-120 (2014).
[cited by applicant]
Bhojwani et al. (2018), “Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia”, Leukemia, Acute lymphoblastic leukemia, accessed at https://doi.org/10.1038/s41375-018-0265-z,…
[cited by applicant]
Bodogai et al. Anti-CD20 Antibody Promotes Cancer Escape via Enrichment of Tumor-Evoked Regulatory B Cells Expressing Low Levels of CD20 and CD137L. Cancer Res 73(7): 2127-2138, 2013.
[cited by applicant]
Borowitz et al. (2015), “Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children's Oncology Group study AALL0232”, Blood, 126(8), 964-971.
[cited by applicant]
Brentjens et al., “CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia,” Science Translational Medicine, 5(177), 177ra38 (2013), 19 pages, Author…
[cited by applicant]
Brentjens et al., “Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by COBO and interleukin-15,” Nature Medicine, 9(3), 279-286 (2003).
[cited by applicant]
Brentjens et al., “Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts,” Clinical Cancer Research, 13(18), 5426-5435 (2007).
[cited by applicant]
Brentjens et al., “Novel cellular therapies for leukemia: CAR-modified T cells targeted to the CD19 antigen,” Hematology. American Society of Hematology. Education Program, 2012, 143-151 (2012).
[cited by applicant]
Brentjens et al., “Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias,” Blood, 118 (18), 4817-4828 (2011).
[cited by applicant]
Brudno et al., “Clinical anti-lymphoma activity and toxicity of T cells expressing a novel anti-CD19 chimeric antigen receptor with fully-human variable regions,” ASCO Meeting Library, abstract cited in J Clin Oncol., 3…
[cited by applicant]
Brudno et al., Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft…
[cited by applicant]
Brudno et al., Chimeric antigen receptor T-cell therapies for lymphoma, Nature Reviews Clinical Oncology 2018, vol. 15, pp. 31-46.
[cited by applicant]
BRüggemann et al. (2017), “Minimal residual disease in adult ALL: technical aspects and implications for correct clinical interpretation”, Blood Advances, 1(25), 2456-2466.
[cited by applicant]
Burns et al., “Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and non mammalian cells,” Proc. Natl. Acad. Sci., USA,…
[cited by applicant]
Cannarile et al. (2017), “Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy”, Journal for Immuno Therapy of Cancer, 5(53), 1-13.
[cited by applicant]
Cao et al., Anti-CD19 Chimeric Antigen Receptor T Cells in Combination With Nivolumab Are Safe and Effective Against Relapsed/Refractory B-Cell Non-hodgkin Lymphoma, Frontiers in Oncology 2019, vol. 9, article 767.
[cited by applicant]
Cartellieri et al., Chimeric Antigen Receptor-Engineered T Cells for Immunotherapy of Cancer. Journal of Biomedicine and Biotechnology 2010, XP055206629, doi:10.1155/2010/956304. 13 pages.
[cited by applicant]
Casan et al. Anti-CD20 monoclonal antibodies: reviewing a revolution. Human Vaccines Immunother 14(12): 2820-2841, 2018.
[cited by applicant]
Champe et al., “Monoclonal Antibodies That Block the Activity of Leukocyte Function-associated Antigen 1 Recognize Three Discrete Epitopes in the Inserted Domain of CD11a”, J Biol Chem, 270(3): 1388-94 (1995).
[cited by applicant]
Chayen, “The role of oil in macromolecular crystallization”, Structure, 5(10): 1269-1274 (1997).
[cited by applicant]
Cheadle et al., “Natural expression of the CD19 antigen impacts the long-term engraftment but not antitumor activity of CD19-specific engineered T cells,” Journal of Immunology, 184 (4), 1885-1896 (2010).
[cited by applicant]
Chen et al., Anti-CD19 Chimeric Antigen Receptor T Cells Improve Responses to Chemotherapy- Refractory Mantle Cell Lymphoma: A Case Report, Blood 2016, vol. 128, No. 22: 5393, DOI: 10.1182/blood.V128.22.5393.5393. 2 pag…
[cited by applicant]
Chen et al., Discovery of Small-Molecule Inhibitors of Hcv NS3-4A Protease as Potential Therapeutic Agents against HCV Infection. Current Medicinal Chemistry 2005, vol. 12, No. 20, doi: 10.2174/0929867054864769, pp. 231…
[cited by applicant]
Cheson et al. (2007), “Revised Response Criteria for Malignant Lymphoma”, Journal of Clinical Oncology, 25(5), 579-586.
[cited by applicant]
Cheson et al. (2014), “Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification”, Journal of Clinical Oncology, 1-10.
[cited by applicant]
Cheung et al., “Epitope-specific antibody response to the surface antigen of duck hepatitis B virus in infected ducks”, Virology 176(2): 546-552 (1990).
[cited by applicant]
Cho et al. Monoclonal Antibody: A New Treatment Strategy against Multiple Myeloma. Antibodies 6: 18, 2017, doi:10.3390/antibod6040018 (22 total pages).
[cited by applicant]
Chothia et al., “Canonical structures for the hypervariable regions of immunoglobulins”, J Mol Biol, 196: 901-917 (1987).
[cited by applicant]
Chothia et al., “Structural repertoire of the human VH segments” J Mol Biol, 227: 799-817 (1992).
[cited by applicant]
Cole et al., In: “Monoclonal Antibodies and Cancer Therapy”, Alan R. Liss, Inc., pp. 77-96 (1985).
[cited by applicant]
Cooper et al., “T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B-lineage leukemia effect,” Blood, 101 (4), 1637-1644 (2003).
[cited by applicant]
Cote et al., Generation of human monoclonal antibodies reactive with cellular antigens, Proc Natl Acad Sci USA, 80 (7): 2026-2030 (1983).
[cited by applicant]
Crotta et al. (2018), “Survival after stem-cell transplant in pediatric and young-adult patients with relapsed and refractory B-cell acute lymphoblastic leukemia”, Curr Med Resin, Opin., 34, 1-18.
[cited by applicant]
Cunningham et al., “High-resolution epitope mapping of hGH-receptor interactions by alanine-scanning mutagenesis”, Science 244(4908): 1081-85 (1989).
[cited by applicant]
Dayhoff et al., “Atlas of Protein Sequence and Structure: A Model of Evolutionary Change in Proteins”, 5: 345-352 (1978).
[cited by applicant]
Deangelo et al. (2017), “32nd Annual Meeting and Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2017): Part One,” Journal for Immuno Therapy of Cancer, 5 (Suppl 2)(86), P217.
[cited by applicant]
Devereux et al., “A comprehensive set of sequence analysis programs for the VAX”, Nucl. Acid Res., 12: 387-395 (1984).
[cited by applicant]
Dolmans et al. (2003), “Photodynamic therapy for cancer”, Nature Reviews, Cancer, 3, 380-397.
[cited by applicant]
Enblad et al., A Phase I/IIa Trial Using CD19-Targeted Third-Generation Car T Cells for Lymphoma and Leukemia, Clinical Cancer Research 2018, vol. 24, No. 24, pp. 6185-6194, DOI: 10.1158/1078-0432.CCR-18-0426.
[cited by applicant]
Eshhar et al., “Tumor-specific T-bodies: towards clinical application”, Cancer Immunol Immunotherapy, 45(3-4):131-136 (1997).
[cited by applicant]
Examination Report for Australian Application No. 2019397033 dated Mar. 9, 2023. 5 pages.
[cited by applicant]
Examination Report for New Zealand Application No. 777087 dated Nov. 20, 2023. 3 pages.
[cited by applicant]
Examiner Requisition for Canadian Application No. 3,122,762 dated Jul. 29, 2022. 4 pages.
[cited by applicant]
Fegan et al. “Chemically controlled protein assembly: techniques and applications”, Chem. Rev., 110(6): 3315-3336 (2010).
[cited by applicant]
Finney et al., “Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product”, Journal of Immunology, 161(6): (1998), Abstract only.
[cited by applicant]
First Examination Report dated Sep. 2, 2021 in GCC Appl. No. GC 2019-38820.
[cited by applicant]
Fishwild et al., “High-avidity human lgG kappa monoclonal antibodies from a novel strain of minilocus transgenic mice.” Nature Biotechnology, 14(7): 845-51 (1996).
[cited by applicant]
Fraietta et al., Determinants of response and resistance to CD19 chimeric antigen receptor (Car) T cell therapy of chronic lymphocytic leukemia, Nature Medicine 2018, vol. 24, pp. 563-571.
[cited by applicant]
Frey et al. (2019), “Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic Leukemia”, Journal of Clinical Oncology, 1-10.
[cited by applicant]
Gen Bank Accession No. ADM64594.1, published Jun. 11, 2012.
[cited by applicant]
Giege et al., “Crystallogenesis of biological macromolecules: facts and perspectives”, Acta Crystallogr D Biol Crystallogr, 50(Pt 4): 339-350 (1994).
[cited by applicant]
Gilead Sciences Announces Fourth Quarter and Full Year 2018 Financial Results?Gilead?Feb. 4, 2019?https://s24.q4cdn.com/804398512/files/doc_news/archive/829f46cd-0ddb-43d5-bedb-3771670d8102.pdf.
[cited by applicant]
Gross et al., “Therapeutic Potential of T Cell Chimeric Antigen Receptors (CARs) in Cancer Treatment: Counteracting Off-Tumor Toxicities for Safe CART Cell Therapy”, Annu. Rev. Pharmacol. Toxicol., 56: 59-83 (2016).
[cited by applicant]
Grupp et al., “Chimeric antigen receptor-modified T cells for acute lymphoid leukemia,” New England Journal of Medicine, 368 (16), 1509-1518 (2013).
[cited by applicant]
Guedan et al., “Engineering and Design of Chimeric Antigen Receptors,” Molecular Therapy: Methods & Clinical Development, 2019, vol. 12, pp. 145-156.
[cited by applicant]
Gupta et al. (2018), “Flow-cytometric vs. —morphologic assessment of remission in childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group (COG)”, Leukemia, Springer Nature, accessed at https:…
[cited by applicant]
Gust et al., Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 Car-T Cells. Cancer Discovery 2017, 7(12), pp. 1404-1419.
[cited by applicant]
Hamilton, “Gm-Csf as a target in inflammatory/autoimmune disease: current evidence and future therapeutic potential”, Expert Reviews, Clin. Immunol., 2015, Early online, accessed at 10.1586/1744666X.2015.1024110, 1-9.
[cited by applicant]
Hay et al., Chimeric Antigen Receptor (Car) T Cells: Lessons Learned from Targeting of CD19 in B-Cell Malignancies. Drugs 2017, doi 10.1007/s40265-017-0690-8. 16 pages.
[cited by applicant]
Hellstrom et al., “Antibodies For Drug Delivery”, in Controlled Drug Delivery (2nd Ed.), Robinson et al. (eds.), Marcel Dekker, Inc., (1987), Abstract only.
[cited by applicant]
Henikoff et al., “Amino acid substitution matrices from protein blocks”, Proc. Natl. Acad. Sci. U.S.A., 89(22): 10915-10919 (1992).
[cited by applicant]
Hermans et al., “The vital assay: a versatile fluorometric technique for assessing CTL- and NKT-mediated cytotoxicity against multiple targets in vitro and in vivo,” Journal of Immunological Methods, 285 (1), 25-40 (200…
[cited by applicant]
Highlights of Prescribing Information for Actemra R (tocilizumab), 2017, 43 pages.
[cited by applicant]
Highlights of Prescribing Information for YESCARTA (axicabtagene ciloleucel), 2017, 31 pages.
[cited by applicant]
Hirayama et al., The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 Car T cells, Blood 2019, vol. 133, No. 17, pp. 1876-1887.
[cited by applicant]
Hombach et al., “Costimulation by chimeric antigen receptors revisited the T cell antitumor response benefits from combined CD28-OX40 signalling,” International Journal of Cancer, 129 (12), 2935-2944 (2011).
[cited by applicant]
Hoogenboom et al., By-passing immunisation: Human antibodies from synthetic repertoires of germline VH gene segments rearranged in vitro, J. Mol. Biol., 227(2): 381-388 (1991).
[cited by applicant]
Hunger et al. (2015), “Acute Lymphoblastic Leukemia in Children”, The New England Journal of Medicine, 373(16), 1541-1552.
[cited by applicant]
Huston et al., “Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli”, Proc Nat Acad Sci USA 85(16):5879- 5883 (1988).
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2020/059285 dated Apr. 12, 2021. 9 pages.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2019/065776 dated Jun. 24, 2020. 21 pages.
[cited by applicant]
Jaffe et al., “Understanding the New WHO Classification of Lymphoid Malignancies: Why It's Important and How It Will Affect Practice,” American Society of Clinical Oncology, 2017, vol. 37, pp. 535-546.
[cited by applicant]
Jain et al. (2019), “Mantle cell lymphoma: 2019 update on the diagnosis, pathogenesis, prognostication, and management”, Annual Clinical Updates in Hematological Malignancies, 94, 710-725.
[cited by applicant]
Jain et al., Axicabtagene ciloleucel (KTE-C19), an anti-CD19 Car T therapy for the treatment of relapsed/refractory aggressive B-cell non-Hodgkin's lymphoma, Therapeutics and Clinical Risk Management 2018, vol. 14, pp. …
[cited by applicant]
Jena et al., Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor. Blood 2010; vol. 116, No. 7, pp. 1035-1044, XP055021403.
[cited by applicant]
Juo, Pei-Show (2002) “Concise dictionary of biomedicine and molecular biology.” second edition, Library of Congress Cataloging-in-Publication Data, CRC Press, 1163.
[cited by applicant]
Kabat et al., “Attempts to locate complementarity-determining residues in the variable positions of light and heavy chains”, Ann NY Acad Sci, 190: 382-391 (1971).
[cited by applicant]
Kalos et al., T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia, Sci. Transl. Med., 3(95): 95ra73 (2011).
[cited by applicant]
Kantarjian et al. (2017), “Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia”, The New England Journal of Medicine, 376(9), 836-847.
[cited by applicant]
Kapoor et al. Anti-CD20 monoclonal antibody therapy in multiple myeloma. Brit J Haematol 141: 135-148, 2008.
[cited by applicant]
Kirkland et al., “Analysis of the fine specificity and cross-reactivity of monoclonal anti-lipid A antibodies”, J. Immunol. 137(11), 3614-2619, (1986).
[cited by applicant]
Kite, A Gilead Company, “A Sutdy Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel (KTE-X19) in Adult Subjects with Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ZUMA-3)”, ClinicalTrials.go…
[cited by applicant]
Klein et al., “Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties,” mAbs 5:1, pp. 22-33 (Year: 2013).
[cited by applicant]
Kochenderfer et al. (2017), “Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels”, Journal of Clinical Oncology, 35(16), 1803-1813.
[cited by applicant]
Kochenderfer et al., “B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells,” Blood, 119(12), 2709-2720 (2012…
[cited by applicant]
Kochenderfer et al., “Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19,” Blood, 116 (20), 4099-4102 (2010).
[cited by applicant]
Kochenderfer et al., “Treating B-cell cancers with T cells expressing anti CD19 chimeric antigen receptors,” Nature Reviews. Clinical Oncology, 10(5), 267-276 (2013).
[cited by applicant]
Kozbor et al., “The production of monoclonal antibodies from human lymphocytes”, Immunol Today, 4(3): 72-9 (1983).
[cited by applicant]
Krause et al., “Antigen-dependent CD28 Signaling Selectively Enhances Survival and Proliferation in Genetically Modified Activated Human Primary T Lymphocytes”, J. Exp. Med., 188(4): 619-626 (1998).
[cited by applicant]
Lackie et al. (2013)The Dictionary of Cell and Molecular Biology, 5th edition, Academic Press, 748 pages.
[cited by applicant]
Lamers et al., “Immune responses to transgene and retroviral vector in patients treated with ex vivo- engineered T cells,” Blood, 117 (1), 72-82 (2011).
[cited by applicant]
Larson et al., Pre-clinical development of gene modification of haematopoietic stem cells with chimeric antigen receptors for cancer immunotherapy, Human Vaccines & Immunotherapeutics 2017, vol. 13, No. 5, 1094-1104.
[cited by applicant]
Latza et al., “The human OX40 homolog: cDNA structure, expression and chromosomal assignment of the ACT35 antigen,” European Journal of Immunology, 24 (3), 677-683 (1994).
[cited by applicant]
Lee et al. (2015), “T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial”, The Lancet, 385, 517-528.
[cited by applicant]
Li et al., A good response of refractory mantel cell lymphoma to haploidentical Car T cell therapy after failure of autologous Car T cell therapy, Journal for ImmunoTherapy of Cancer 2019, vol. 7, No. 51. 7 pages.
[cited by applicant]
Ling et al., “Advances in cancer immunotherapy based on chimeric antigen receptor,” Translational Med. J., 4 (3), 97-104 (2015).
[cited by applicant]
Lippow et al., “Computational design of antibody-affinity improvement beyond in vivo maturation,” Nature Biotechnology, 25(10) pp. 1171-1176. (Year: 2007).
[cited by applicant]
Littman et al., The isolation and sequence of the gene encoding T8: A molecule defining functional classes of T lymphocytes, Cell 1985, vol. 40, pp. 237-246.
[cited by applicant]
Liu et al., Current approaches and advance in mantle cell lymphoma treatment, Stem Cell 2015, 2;18.
[cited by applicant]
Lo et al., “Conformational epitope matching and prediction,” BMC Genomics, 22(Suppl 2) pp. 1-16 (Year: 2021).
[cited by applicant]
Lonberg et al. “Human antibodies from transgenic mice”, Intern. Rev. Immunol., 13(1) 65-93 (1995).
[cited by applicant]
Lonberg et al., “Antigen-specific human antibodies from mice comprising four distinct genetic modifications”, Nature, 368(6474): 856-859 (1994).
[cited by applicant]
Mangogna et al. Rituximab Plus Chemotherapy Provides No. Clinical Benefit in a Peripheral T-Cell Lymphoma not Otherwise Specified with Aberrant Expression of CD20 and CD79a: A Case Report and Review of the Literature. D…
[cited by applicant]
Mannering et al., “A sensitive method for detecting proliferation of rare autoantigen-specific human T cells,” Journal of Immunological Methods, 283 (1-2), 173-183 (2003).
[cited by applicant]
Marks et al., “By-passing immunization. Human antibodies from V-gene libraries displayed on phage”, J. Mol. Biol., 22(3):581-97 (1991).
[cited by applicant]
Marks et al., “By-passing immunization: building high affinity human antibodies by chain shuffling”, Biotechnology, 10(7):779-783 (1992).
[cited by applicant]
Martin et al., “Postibrutinib outcomes in patients with mantle cell lymphoma”, Clinical Trials and Observations, Blood, vol. 127, No. 12, Mar. 24, 2016, pp. 1559-1563.
[cited by applicant]
Maude et al. (2018), “Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia”, The New England Journal of Medicine, 378(5), 439-448.
[cited by applicant]
McPherson, Jr., “Crystallization of Proteins from Polyethylene Glycol”, J Biol Chem, 251 (20): 6300-6303 (1976).
[cited by applicant]
McPherson, “Current approaches to macromolecular crystallization”, Eur J Biochem, 189: 1-23 (1990).
[cited by applicant]
Moldenhauer et al., Identity of HML-1 Antigen on Intestinal Intraepithelial T Cells and of B-ly7 Antigen on Hairy Cell Leukaemia, Scandinavian Journal of Immunology, 32(2): 77-82 (1990).
[cited by applicant]
Moran et al., “The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy,” Current Opinion in Immunology, 25 (2), 230-237 (2013).
[cited by applicant]
Morel et al., “Monoclonal antibodies to bovine serum albumin: affinity and specificity determinations”, Mol Immunol, 25(1): 7-15 (1988).
[cited by applicant]
Morrison, “Success in specification”, Nature, 368, 812-13 (1994) 10.1038/368812a0.
[cited by applicant]
Nadler et al., “B4, a human B lymphocyte-associated antigen expressed on normal, mitogen-activated, and malignant B lymphocytes,” Journal of Immunology, 131 (1), 244-250 (1983).
[cited by applicant]
Neelapu, 2-Year Follow-up and High-Risk Subset Analysis of Zuma-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Refractory Large B Cell Lymphoma Sattva S. Neelapu MD Abstracts / Biol Blood Mar…
[cited by applicant]
Neelapu et al. (2018), “Chimeric antigen receptor T-cell therapy - assessment and management of toxicities”, Nature Reviews, Clinical Oncology, 15, 47-62.
[cited by applicant]
Neelapu et al., “Kte-C19 (anti-CD19 Car T Cells) Induces Complete Remissions in Patients with Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Results from the Pivotal Phase 2 Zuma-1,” Blood, 2016, Abstract.
[cited by applicant]
Neuberger, “Generating high-avidity human Mabs in mice”, Nature Biotechnology, 14: 826 (1996).
[cited by applicant]
Nguyen et al. (2008), “Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children's Oncology Group study”, Leukemia, 22, 2142-2150.
[cited by applicant]
Nicholson et al., “Construction and characterisation of a functional CD19 specific single chain Fv fragment for immunotherapy of B lineage leukaemia and lymphoma,” Molecular Immunology, 34 (16-17), 1157-1165 (1997).
[cited by applicant]
Notice of Preliminary Rejection for Korean Application No. 10-2021-7021608 dated Oct. 20, 2024. 4 pages.
[cited by applicant]
Notice of Preliminary Rejection for Korean Application No. 10-2021-7021608 dated Feb. 26, 2024. 6 pages.
[cited by applicant]
Notice of Preliminary Rejection for Korean Application No. 10-2021-7021608 dated Aug. 18, 2023. 17 pages.
[cited by applicant]
Ochi et al., “Functional immunoglobulin M production after transfection of cloned immunoglobulin heavy and light chain genes into lymphoid cells,” Proceedings of the National Academy of Sciences of the United States of …
[cited by applicant]
Office Action and Search Report for Taiwan Application No. 110125603 dated Oct. 31, 2023. 20 pages.
[cited by applicant]
Office Action for Canadian Application No. 3,122,762 dated Nov. 4, 2024. 3 pages.
[cited by applicant]
Office Action for Canadian Application No. 3,122,762 dated Sep. 18, 2023. 7 pages.
[cited by applicant]
Office Action for Canadian Application No. 3,177,829 dated Feb. 23, 2024. 5 pages.
[cited by applicant]
Office Action for Chinese Application No. 201980091506.9 dated Aug. 7, 2024. 15 pages.
[cited by applicant]
Office Action for Chinese Application No. 201980091506.9 dated Mar. 18, 2024. 19 pages.
[cited by applicant]
Office Action for Israeli Application No. 283734 dated Oct. 26, 2023. 5 pages.
[cited by applicant]
Office Action for Japanese Application No. 2021-533159 dated Jan. 10, 2023. 4 pages.
[cited by applicant]
Office Action for Japanese Application No. 2021-533159 dated Jul. 5, 2022. 10 pages.
[cited by applicant]
Office Action, issued in TW Application No. 108145595, dated Jan. 13, 2021.
[cited by applicant]
Oskarsson et al. (2016), “Relapsed childhood acute lymphoblastic leukemia in the Nordic countries: prognostic factors, treatment and outcome”, Acute Lymphoblastic Leukemia, Haematologica, 101(1), 68-76.
[cited by applicant]
Park et al. (2018), “Long-Term Follow-up of CD19 Car Therapy in Acute Lymphoblastic Leukemia”, The New England Journal of Medicine, 449-459.
[cited by applicant]
Partial Supplementary European Search Report for European Application No. 20886085.8 dated Apr. 5, 2024. 23 pages.
[cited by applicant]
Patel et al., T-cell killing of heterogenous tumor or viral targets with bispecific chimeric immune receptors. Cancer Gene Therapy 2000, vol. 7, No. 8, pp. 1127-1134, XP055259929.
[cited by applicant]
Pinchera et al. (eds.), “Analysis, Results, And Future Prospective Of The Therapeutic Use Of Radiolabeled Antibody In Cancer Therapy”, in Monoclonal Antibodies For Cancer Detection And Therapy, pp. 475-506 (1985).
[cited by applicant]
Porter et al., “Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia”, N. Engl. J. Med., 365(8):725-33 (2011).
[cited by applicant]
Porter et al., “Comparison of efficiency of infection of human gene therapy target cells via four different retroviral receptors,” Human Gene Therapy, 7 (8), 913-919 (1996).
[cited by applicant]
Raboisson et al., Structure-activity relationship study on a novel series of cyclopentane-containing macrocyclic inhibitors of the hepatitis C virus NS3/4A protease leading to the discovery of TMC435350. Bioorganic & Me…
[cited by applicant]
Ramos et al., “CAR-T Cell Therapy for Lymphoma,” Annu. Rev. Med. 67, pp. 165-183 (Year: 2016).
[cited by applicant]
Ren et al., Multiplex Genome Editing to Generate Universal Car T Cells Resistant to PD1 Inhibition, Clin Cancer Res 2017; 23(9); 2255-2266.
[cited by applicant]
Rheingold et al. (2019), “Prognostic factors for survival after relapsed acute lymphoblastic leukemia (All): A Children's Oncology Group (COG) study”, Journal of Clinical Oncology, List of Issues, 37(15), 1-5.
[cited by applicant]
Rosenberg et al., “Adoptive cell transfer as personalized immunotherapy for human cancer”, Cancer Immunology and Immunotherapy, 348: 62-68 (2015).
[cited by applicant]
Rubio et al., “Ex vivo identification, isolation and analysis of tumor-cytolytic T cells,” Nature Medicine, 9 (11), 1377-1382 (2003).
[cited by applicant]
Ruella et al., The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma, Clinical Cancer Research, 2016, 22(11):2684-2696.
[cited by applicant]
Sabatino et al., “Production of Anti-CD19 Car T Cells for ZUMA-3 and -4: Phase 1/2 Multicenter Studies Evaluating KTE-C19 in Patients With Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (R/R All)”, Blood, …
[cited by applicant]
Sadelain et al., “Targeting Tumors with Genetically Enhanced T Lymphocytes”, Nature Rev. Cancer, 3: 35-45 (2003).
[cited by applicant]
Sadelain et al., CD19 Car Therapy for Acute Lymphoblastic Leukemia, American Society of Clinical Oncology Educational Book 2015, e360-e363.
[cited by applicant]
Salles et al. Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience. Adv Ther 34: 2232-2273, 2017.
[cited by applicant]
Savoldo et al., “CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients,” Journal of Clinical Investigation, 121 (5), 1822-1826 (2011).
[cited by applicant]
Schneider et al., Minimizing leukemia escape: implementing a dual anti-CD20- and CD19-scFv-based chimeric antigen receptor (CAR). Journal for Immuno Therapy of Cancer 2015, vol. 3, No. 2, doi:10.1186/2051-1426-3-S2-P122…
[cited by applicant]
Schrappe et al. (2012), “Outcomes after Induction Failure in Childhood Acute Lymphoblastic Leukemia”, The New England Journal of Medicine, 366(15), 1371-1381.
[cited by applicant]
Schuster et al. (2019), “Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma”, The New England Journal of Medicine, 380(1), 45-56.
[cited by applicant]
Schuster et al., “Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas,” The New England Journal of Medicine, 2017, vol. 377, pp. 2545-2554.
[cited by applicant]
Shah et al., “End of phase I results of ZUMA-3, a phase 1/2 study of KTE-X19, anti-CD19 chimeric antigen receptor (Car) T cell therapy, in adult patients (pts) with relapsed/refractory (R/R) acute lymphoblastic leukemia…
[cited by applicant]
Shah et al., A Phase 1 Study with Point-of-Care Manufacturing of Dual Targeted, Tandem Anti-CD19, Anti-CD20 Chimeric Antigen Receptor Modified T (Car-T) Cells for Relapsed, Refractory, Non-Hodgkin Lymphoma, Blood 2018, …
[cited by applicant]
Shah, B et al., “High Rates of Minimal Residual Disease-Negative (MRD-) Complete Responses (CR) in Adult and Pediatric and Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia (R/R All) Treated with KTE-C19 (a…
[cited by applicant]
Sommermeyer et al., Fully human CD19-specific chimeric antigen receptors for T-cell therapy, Leukemia 31(10): 2191-2199 (2017).
[cited by applicant]
Song et al., “CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo”, Blood, 119(3): 696-706 (2012).
[cited by applicant]
Sotillo et al. (2015), “Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy”, Cancer Discovery, OF1-OF14.
[cited by applicant]
Stackelberg et al. (2016), “Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia”, Journal of Clinical Oncology, 34(36), 4381-4389.
[cited by applicant]
Stahli et al., “Distinction of epitopes by monoclonal antibodies”, Methods in Enzymology, 92: 242-253 (1983).
[cited by applicant]
Sun et al. (2018), “Outcome of children with multiply relapsed B-cell acute lymphoblastic leukemia: a therapeutic advances in childhood leukemia & lymphoma study”, Acute lymphoblastic leukemia, Springer Nature, 32, 2316…
[cited by applicant]
Swerdlow et al., “The 2016 revision of the World Health Organization classification of lymphoid neoplasms,” Blood, 2016, vol. 127, No. 20, 16 pages.
[cited by applicant]
Tammana et al., 4-1BB and CD28 Signaling Plays a Synergistic Role in Redirecting Umbilical Cord Blood T Cells Against B-Cell Malignancies, Human Gene Therapy 2010 , 21, pp. 75-86.
[cited by applicant]
Thorpe et al., Monoclonal antibodies ″84: biological and clinical applications : Proceedings of the International Symposium on Monoclonal antibodies ″84 held in Florence, Italy, Oct. 16-19 (1984).
[cited by applicant]
Thorpe et al., “The preparation and cytotoxic properties of antibody-toxin conjugates”, Immunol. Rev., 62: 119-58 (1982).
[cited by applicant]
Topp et al. (2014), “Safety and activity of blinatumomab for adult patients with relapsed or refractory B- precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study”, The Lancet, 16, 57- 66.
[cited by applicant]
Tramontano et al., “Framework residue 71 is a major determinant of the position and conformation of the second hypervariable region in the VH domains of immunoglobulins” J Mol Biol, 215(1):175-82 (1990).
[cited by applicant]
Turtle et al., Immunotherapy of non-Hodgkin lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells, Science Translational Medicine 2016, vol. 8, No. 355, doi:10.1126/scit…
[cited by applicant]
UniprotKB-P01732 (CD8A Human) (12 pages) Jul. 21, 1986.
[cited by applicant]
Urbanska et al., Targeted cancer immunotherapy via combination of designer bispecific antibody and novel gene-engineered T cells. Journal of Translational Medicine 2014, vol. 12, No. 1, XP021207565. 12 pages.
[cited by applicant]
Venkatraman et al., Macrocyclic inhibitors of Hcv NS3 protease. Expert Opinion on Therapeutic Patents 2009, vol. 19, No. 9, doi: 10.1517/13543770903044994, pp. 1277-1303, XP055084885. https://doi.org/10.1517/13543770903…
[cited by applicant]
Wang et al. (2017), “Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial”, The Lancet, 1-9.
[cited by applicant]
Wang et al. (2020), “KTE-X19 Car T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma”, The New England Journal of Medicine, 382(14), 1331-1342.
[cited by applicant]
Wang et al., Safety and preliminary efficacy in patients (pts) with relapsed/refractory (R/R) mantle cell lymphoma (MCL) receiving lisocabtagene maraleucel (Liso-cel) in Transcend Nhl 001, Journal of Clinical Oncology, …
[cited by applicant]
Wang et al., ZUMA-2: A phase 2 multi-center study evaluating the efficacy of KTE-C19 (Anti-CD19 Car T cells) in patients with relapsed/refractory mantle cell lymphoma (R/R MCL), Annals of Oncology, 2016, vol. 27(Supplem…
[cited by applicant]
Weinberg et al., “Science gone translational: the OX40 agonist story,” Immunological Reviews, 244 (1), 218-231 (2011), Author Manuscript.
[cited by applicant]
White et al. Cancer Prevention for the Next Generation. J Adolesc Health 52: S1-S7, 2013.
[cited by applicant]
Wicks et al. (2015), “Targeting GM-CSF in inflammatory diseases”, Nature Reviews, Rheumatology, 1-12.
[cited by applicant]
Wong et al., “Ab-Ligity: identifying sequence-dissimilar antibodies that bind to the same epitope,” MABS, vol. 13, No. 1 pp. 1-8 (Year: 2021).
[cited by applicant]
Wu et al., “Remote control of therapeutic T cells through a small molecule-gated chimeric receptor”, Science, 350:6258 (2014).
[cited by applicant]
Yang et al., “A simplified method for the clinical-scale generation of central memory-like CDS+ T cells after transduction with lentiviral vectors encoding antitumor antigen T-cell receptors,” Journal of Immunotherapy, …
[cited by applicant]
Yoon-Hwan, “High-grade B-cell lymphoma,” Korean Society for Laboratory Hematology News Letter, 2017, vol. 23, 3 pages.
[cited by applicant]
Zebedee et al., “Human combinatorial antibody libraries to hepatitis B surface antigen”, Proc. Natl. Acad. Sci. USA, 89(8): 3175-79 (1992).
[cited by applicant]
Zhao et al. Universal CARs, universal T cells, and universal CART cells. J Hematol Oncol 11: 132, 2018, 9 pages.
[cited by applicant]
Decision of Final Rejection for Japanese Application No. 2023-132752 dated Aug. 5, 2025, 4 pages.
[cited by applicant]
“Hematopoietic and Lymphoid Tumors—WHO Classification, 2016 Version,” Journal of Clinical Laboratory Medicine, vol. 61., No. 7, 2017, pp. 847-888.
[cited by applicant]
Kochenderfer et al., Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells. Blood. Nov. 11, 2010;116(19):3875-86.
[cited by applicant]
Penfold et al., “The FDA grants KTE-C19 Priority Review for the treatment of transplant-ineligible relapsed/refractory Non-Hodgkin Lymphoma,” LymphomaHub, 2017, 1 page.
[cited by applicant]
Gore L. et al. “Survival after blinatumomab treatment in pediatric patients with relapsed/refactory B-cell precursor acute lymphoblastic leukemia”, Blood Cancer J. Aug. 22, 2018; 8(9):80. (Year 2018).
[cited by applicant]
Kansagra Aj et al. “Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)—an expert opinion from the (EBMT) and the (ASBMT)”, Bone Marrow Transplant. Nov. 2019; 5…
[cited by applicant]
Paul S et al. “Adult-Acute Lymphoblastic Leukemia” Symposium on neoplastic hematology and medical oncology, vol. 91 Issue 11 p. 1645-1666 Nov. 2016 (Year 2016).
[cited by applicant]
Schneider et al: “A tandem CD19/CD20 Car lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines”, Journal for Immunotherapy of Cancer, Biomed Central Ltd, London, UK, vol. 5, No. 1, …
[cited by applicant]
Zah et al: “T Cells Expressing CD19/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B Cells”, Cancer Immunology Research, vol. 4, No. 6, Apr. 8, 2016 (Apr. 8, 2016), pp. 498-508, XP0552909…
[cited by applicant]